All Oncology News

The European Commission has expanded the approval of azacitidine in acute myeloid leukemia to include patients aged ≥65 years who are ineligible for hematopoietic stem cell transplantation and who have >30% myeloblasts.

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

Jennifer R. Brown, MD, PhD, discusses the future of chronic lymphocytic leukemia treatment.

Dozens of genetic abnormalities, including 44 mutated genes and 11 recurrent somatic copy number variations, were found to potentially play a role in progression and/or relapse of chronic lymphocytic leukemia.

ASCO has issued a position paper against "site-neutral" Medicare payments that would reduce the wide disparity between hospital costs and physician practice costs for similar services.

Determining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Rolling submission of a new drug application for cabozantinib has been initiated for patients with advanced renal cell carcinoma who have received one prior therapy.

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

The FDA has approved trabectedin for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline.

The FDA issued a complete response letter to Spectrum Pharmaceuticals, informing the company that its new drug application (NDA) for the use of Captisol-enabled melphalan in multiple myeloma will not be approved in its current form.

The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.

The American Cancer Society now recommends that women at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45.

Novel agents have transformed the treatment of mantle cell lymphoma and tumor profiling is poised to further enhance these benefits.

Medical oncologist Lori J. Goldstein, MD, from Fox Chase Cancer Center, have been looking at reparixin, an investigational study drug that targets breast cancer stem cells.

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis.

The National Cancer Institute has named Craig Crews, PhD, a recipient of its Outstanding Investigator Award.

Kentucky's only NCI cancer center, Markey focuses on bringing the latest therapies to its home state.

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

Hans-Christian Kolberg, MD, discusses updated results from a study that showed that neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab demonstrated significant overall survival and disease-free survival activity in patients with HER2-positive early-stage breast cancer.

The FDA has granted the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin a breakthrough therapy designation as a potential treatment for acute lymphoblastic leukemia.

Kimberly L. Blackwell, MD, discusses the potential for some emerging therapies, as well as the benefits of current treatments for patients with HER2-positive breast cancer.

The nation's leading digital and print resource for oncology professionals, OncLive, announced today it is doubling the frequency of its flagship publication, OncologyLive, to keep pace with the quickly evolving oncology marketplace. Starting in January, the clinical news publication will publish twice a month, with expanded coverage of emerging therapeutic strategies and research developments.

Internationally renowned clinician-scientist Alec Kimmelman, MD, PhD, has been named Chair of the Department of Radiation Oncology at NYU Langone Medical Center. His appointment is effective February 1, 2016.